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ABSTRACT 
This study was carried out at the Small Animal Clinic, Faculty of Veterinary Medicine, 
National University of San Marcos (Universidad Nacional Mayor de San Marcos, UNMSM), 
Lima, Peru during the period 10th of September – 2nd of November 2012. Ten dogs with a 
positive serologic result on the Microscopic Agglutination Test (MAT), serovars australis, 
bratislava, canicola, georgia, grippotyphosa, icterohaemorrhagiae and pomona included, were 
included in the study. All specimens were examined and treated at UNMSM or GuauGuau 
Wasi, a private owned small animal clinic in Lima. Serology, hematology, blood chemistry 
(urea, creatinine, total protein, albumin, alanine aminotransferase (ALT), alkaline phosphatase 
(ALKP) and phosphate) and urinalysis were evaluated both before and after treatment. The 
most common clinical signs in the dogs studied were depression (n=6), vomiting (n=5), 
diarrhea (n=4) and polydipsia (n=4). The most common treatment was doxycycline (5 mg/kg 
every 12 hours, orally) although clinically unstable dogs received treatment with 
benzylpenicillin, amoxicillin or ampicillin prior to an oral treatment with doxycycline at 
home. A decrease was observed at the p=0,05 level of significance in leucocytes and 
neutrophiles in blood and also in proteinuria after treatment, however most of the dogs still 
maintained levels of neutrophiles and proteinuria above that of the reference range used by 
the Laboratory of Clinical Pathology at UNMSM after treatment. None of the dogs in the 
study were known to have anemia. None of the blood chemistry parameters showed a 
significant decrease (p=0,05). However all the dogs with initially increased levels of 
creatinine (2/10), ALT (3/8) or ALKP (4/7) had decreased values after treatment, however 
many still had a value above the reference range. Increased urea levels (8/10) reduced after 
treatment in five of eight dogs, however the other dogs’ (3/8) urea levels continued to increase 
after treatment. 
 
 
 
  
 
 
 
 
 
 
  
 8 
 
SAMMANFATTNING  
Denna studie gjordes på smådjurskliniken, Veterinärmedicinska fakulteten, nationella 
universitetet San Marcos (Universidad Nacional Mayor de San Marcos, UNMSM), Lima, 
Peru under perioden 10 september – 2 november 2012. Tio hundar med ett positivt resultat på 
ett Microskopiskt Agglutinations Test (MAT), serovarer australis, bratislava, canicola, 
georgia, grippotyphosa, icterohaemorrhagiae, pomona inkluderade, inkluderades i studien. 
Alla hundar var undersökta och behandlade på UNMSM eller GuauGuau Wasi, en privatägd 
smådjursklinik i Lima. Serologi, hematologi, blodkemiska tester (urea, kreatinin, total protein, 
albumin, alanin aminotransferas (ALT), alkalin fosfatas (ALKP) och fosfat) och urinprov 
undersöktes både före och efter behandling. De vanligaste sjukdomstecknen hos de studerade 
hundarna var depression (n=6), kräkningar (n=5), diarré (n=4) och polydipsi (n=4). Den 
vanligaste behandlingen var doxycyklin (5 mg/kg var 12:e timme, oralt) även om kliniskt 
instabila patienter fick behandling med bensylpenicillin, amoxicillin eller ampicillin före en 
oral behandling med doxycyklin inleddes hemma. En sänkning observerades på 
signifikansnivån p=0,05 för leukocyter och neutrofiler i blodet samt proteinuri efter 
behandling, men många av hundarna hade dock fortfarande nivåer av blodneutrofiler och 
proteinuri över de normala referensvärdena som används på laboratoriet för klinisk patologi 
på UNMSM efter behandling. Anemi observerades inte hos någon av hundarna i studien. 
Ingen av blodkemiparametrarna visade en signifikant sänkning (p=0,05). Dock hade alla 
hundar med stegrat kreatinin (2/2), ALT (3/8) eller ALKP (4/7) minskade nivåer efter 
behandling, men många av dem hade fortfarande nivåer över de normala referensvärdena. 
Stegrade ureanivåer (8/10) sjönk efter behandling hos fem av åtta hundar, men de övriga 
hundarnas (3/8) ureanivåer fortsatte att stiga efter behandling. 
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INTRODUCTION 
The bacterium Leptospira can be found all over the world but leptospirosis as a disease is 
more common in countries with a warm, humid climate that allow the bacteria to thrive 
(Levett, 2001: Sykes et al., 2011). Leptospira is a Gram-negative, aerobic bacterium (Holt, 
1978; Zuerner, 2010), of which there are both pathogenic and saprophytic strains (Faine & 
Stallman, 1982; Johnson & Harris, 1967). Almost every known species of rodent, mammal or 
marsupial (including humans) can be a reservoir or incidental host for Leptospira (Babudieri, 
1958; Faine et al., 1999; Levett, 2001; Picardeau, 2013). The serovars bratislava, canicola, 
icterohaemorrhagiae, grippotyphosa and pomona are most frequently reported in dogs. 
Leptospirosis can affect many organs including the blood vessels, liver and kidneys (Arent et 
al., 2012; Miller et al., 2011). The incubation period is approximately seven days, depending 
on dose, strain and host (Sykes et al., 2011). The Microscopic Agglutination Test (MAT) is 
the standard method for serologic diagnosis of leptospirosis (Levett, 2001).  
 
The serological prevalence of leptospirosis in dogs in South America varies between 
countries. In a study from the district Chancay, Lima, Peru a seroprevalence of 27,8% 
(67/241) was found in the dogs (Céspedes et al., 2007). Ciceroni et al. (1997) found a 
seroprevalence of 14% (6/43) in Bolivia in 1992. In a Columbian seroprevalence study from 
2007 at least 21,4% (182/850) of the dogs had a positive result on MAT (Romero et al., 
2010). Another Colombian study from 2004 found an incidence of 41,1% (81/197) 
(Rodríguez et al., 2004). These results indicate that leptospirosis is a highly problematic 
disease for dogs in South America. Leptospirosis is considered a rare disease in Swedish dogs 
with 16 cases reported in 2011 and 18 in 2010 (The Swedish Board of Agriculture (SJV), 
2010 & 2012).  
 
In this study the changes in serology, hematology, blood chemistry and urinalysis are 
described in ten dogs, both prior to and one month after treatment. This description will 
hopefully give veterinarians more information about possible changes in blood and urine and 
the effect of treatment in dogs with leptospirosis. It is important to be able to diagnose and 
treat leptospirosis in dogs, both for the health of the dog (and therefore the mental wellbeing 
of the owner) and the health of the owners themselves, as leptospirosis is a zoonotic disease.  
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Fig 1. Artist’s impression of a Leptospira 
bacterium.  
Source: 
http://www.leptospirosis.org/downloads/e
msim-leptospira-interrogans-02.png 
 
PART 1, LITERATURE OVERVIEW: LEPTOSPIRA AND LEPTOSPIROSIS 
Etiology 
The bacterium 
Leptospira is a Gram-negative, aerobic bacterium that belongs to the order Spirochaetales, 
family Leptospiracae and genus Leptospira 
(Holt, 1978; Zuerner, 2010). The bacterium, 
illustrated in Figure 1, has a helical appearance 
with a hook on each end and is as thin as a 
sewing thread (0,1 x 6-20 µm) (Holt, 1978). It is 
motile through two periplasmic flagella (Levett, 
2001). The bacterium has an inner membrane and 
an outer membrane containing 
lipopolysaccharides (LPS) (Holt, 1978).  
 
Leptospira bacteria prefer a moist, warm 
environment, with an optimal growth temperature 
of 28-30oC (McDonough, 2001; Zuerner, 2010). 
There are both saprophytic and pathogenic strains 
of Leptospira and an important difference between them is that saprophytic strains reproduce 
at a temperature of 13oC, however the pathogenic do not (Johnson & Harris, 1967). Both 
strains are sensitive to dry environments and are inhibited by pH<6 and pH>8 (McDonough, 
2001). In a preferable environment the leptospires can survive for a long time (Levett, 2001). 
According to McDonough (2001) they can survive up to 180 days in wet soil and for many 
months in surface water.  
 
Taxonomy 
Previously the genus Leptospira was divided into the two species: L. interrogans (pathogenic 
strains) and L. biflexa (saprophytic strains) (Faine & Stallman, 1982). By using antibodies 
against LPS the two species were divided into multiple serovars. Serovars that were 
antigenically related and cross-reacted when using serological methods formed a serogroup 
(Dikken & Kmety, 1978; Zuerner, 2010). In L. biflexa there are more than 60 serovars and in 
L. interrogans more than 200 (Levett, 2001). With modern methods, such as DNA 
hybridization, the leptospires can be divided into genomospecies. In one genomospecie both 
pathogenic and saprophytic serovars can be found (Brenner et al., 1999). At the Laboratory of 
Bacteriology at the National University of San Marcos (Universidad Nacional Mayor de San 
Marcos, UNMSM), in Lima, Peru, the serovars in Table 1 are analyzed via MAT.  
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Table 1. Serovars analyzed at UNMSM with their serogroups and genomospecies (after Brenner et al. 
1999)  
SEROVAR Serogroup Genomospecies 
Australis Australis interrogans, kirschneri, noguchii, borgpetersenii 
Bratislava Australis Interrogans 
Canicola Canicola interrogans, kirschneri, inadai 
Georgia Mini interrogans, weilii, santarosai, borgpetersenii, meyeri, alexanderi 
Grippotyphosa Grippotyphosa interrogans, kirschneri, santarosai 
Icterohaemorrhagiae Icterohaemorrhagiae interrogans, borgpetersenii, noguchii, inadai, genomospecies 4 
Pomona Pomona interrogans, kirschneri, noguchii, santarosai 
 
Epidemiology 
Geography and climate 
Cases of leptospirosis are more frequently seen in countries with a warm climate. Many 
tropical countries are low-income countries which could increase the prevalence as animals 
live closer to each other, sanitary problems could be present etc. (Levett, 2011; Sykes et al., 
2011). In a study by Boqvist et al. (2012) a positive correlation between rainfall and 
seropositivity for leptospirosis in pigs was found in Sweden. Adin & Cowgill (2000) found a 
positive correlation between rainfall and leptospirosis in dogs in San Francisco, California, 
USA.  
 
Reservoir and incidental hosts 
The serovars have different reservoir hosts (in various studies called maintenance hosts) and 
incidental hosts (Levett, 2001). The reservoir hosts are believed to suffer from a chronic 
infection with Leptospira in their kidneys, as the leptospires colonize the surface of renal 
proximal tubular epithelial cells (Adler & Moctezuma, 2010; Babudieri, 1958; Picardeau, 
2013). The hosts do not necessarily host all serovars of Leptospira but can simultaneously 
host multiple serovars. Whether or not an animal becomes a reservoir host depends on many 
factors, such as, for example, urine pH in the host, environment and possibilities of coming 
into contact with the bacterium. If two animals of a potential reservoir species are infected 
one of them can become a reservoir host while the other does not. An infected incidental host 
will experience more severe clinical signs than a reservoir host (Babudieri, 1958). Almost 
every known species of rodent, mammal or marsupial can be a reservoir or incidental host for 
Leptospira (Faine et al., 1999; Picardeau, 2013). As humans can also be infected, 
leptospirosis is classified as a zoonotic disease.  
 
Transmission  
Leptospirosis can be transmitted directly between host animals or indirectly via the 
environment (Adler & Moctezuma, 2010; Levett, 2001). Direct transmission can occur when 
an animal has contact with blood or other body fluids from an infected animal (incidental 
host) or a reservoir host. Transmission when in contact with infected urine is common (Faine 
et al., 1999; Forbes et al., 2012; Ngbede et al., 2012; Picardeau, 2013). The reservoir hosts are 
important in this aspect as they can secrete leptospires in their urine for a long time, even 
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throughout their entire life (Babudieri, 1958; Faine et al., 1999). Direct transmission also 
occurs through bites, consumption of infected viscera, inhalation of aerosols or contaminated 
water, sexual contact, transplacentally and transmammary. Direct, non-waterborne 
transmission between humans and dogs is only rarely reported and more studies are necessary 
to investigate this kind of transmission. Indirect transmission occurs when an animal comes 
into contact with water contaminated with urine or other body fluids from infected animals, 
for example in areas where there are infected rodents (Faine et al., 1999; Forbes et al., 2012; 
Levett, 2001; Ngbede et al., 2012). The leptospires can survive for a long time in diluted urine 
but outside the host animal they do not replicate (Babudieri, 1958).  
 
Pathogenesis 
The bacterium enters the body via intact mucous membranes (mouth, nose, eyes) or a skin 
with lesions and scratches (Adler & Moctezuma, 2010; Forbes et al., 2012; Langston & 
Heuter, 2003). Through lymphatic vessels from the infection site the leptospires enter the 
bloodstream (Faine et al., 1999). In the bloodstream the bacteria will multiply and spread to 
organs such as the kidneys, spleen, central nervous system, liver, eyes or reproductive organs 
(Langston & Heuter, 2003). There are three possible pathways after the systemic circulation. 
If the animal has a high and adequate antibody titer the body will be cleared from leptospires 
and no clinical signs can be seen. An animal with a moderate antibody can present with a mild 
or short leptospiremia followed by mild clinical signs. The leptospires are then eliminated 
through the kidneys and after the elimination the animal will not continue to shed leptospires. 
If the animal has a low or absent antibody titer there will be a multiplication of leptospires in 
the bloodstream. The endothelium will be damaged which can cause ischemia in different 
organs such as the kidneys (renal tubular necrosis), liver (hepatocellular damage) or lungs 
(Adler & Moctezuma, 2010; Greene et al., 2006; Langston & Heuter, 2003). Neutrophils and 
thrombocytes are stimulated by LPS in the outer membrane of the leptospires and this 
contributes to inflammation and coagulatory abnormalities (Langston & Heuter, 2003). The 
LPS can contribute to the renal and hepatic damage. Meningitis can develop if the leptospires 
enter the nervous system or cerebral spinal fluid in the acute phase of the disease. If bacteria 
persist despite the antibody response, then immune-complex-mediated meningitis can occur. 
When this phenomenon occurs in the eyes it causes uveitis (Faine et al., 1999; Greene et al., 
2006).   
 
The incubation period of leptospirosis depends on dose, infectious strain and host but is 
approximately seven days (Sykes et al., 2011). According to Levett (2001) antibodies become 
detectable 5-7 days after infection. It takes about two weeks for the leptospires to reach the 
proximal tubular cells and the tubular lumen in the kidneys (Greene at al., 2006). In the best 
case scenario, the antibodies will clear the blood and tissues from leptospires. The bacteria 
can also become eliminated from the kidneys and no leptospires will thus be shed in the urine. 
In some animals, despite an increased antibody titer, the bacteria can replicate and persist in 
the renal tubular cells. This may result in chronic shedding of leptospires in the urine for days 
to months, even years (Faine et al., 1999; Greene et al., 2006; Langston & Heuter, 2003). 
Leptospira can give permanent lesions in internal organs. An organ can be severely affected 
even though the animal recovers clinically (Greene et al., 2006). 
 13 
 
Clinical findings  
Clinical signs 
In various studies anorexia, lethargy/depression and vomiting were the three most common 
clinical signs in dogs with leptospirosis. Weight loss, polyuria/polydipsia, diarrhea, abdominal 
or lumbar pain, musculoskeletal pain and dehydration were also common (Birnbaum et al., 
1998; Goldstein et al., 2006; Greenlee et al., 2004; Prescott et al., 2002). Intestinal 
intussusceptions have occurred in dogs with gastrointestinal involvement. Ventricular 
tachyarrhythmia and eventual myocardial damage can occur in dogs where the heart is 
involved (Greene et al., 2006). Uveitis has also been observed. In other animals such as cattle, 
pigs and horses abortion is common but this is rarely the case with dogs (Picardeau, 2013). 
Young animals often get a more severe form of leptospirosis compared to adults (Greene et 
al., 2006). 
 
It is tempting to correlate the different serovars and serogroups to specific clinical features, 
however this would be inappropriate as serovars that are classed in the same serogroup but are 
from different geographic areas can have different pathogenicity, hosts and genetic 
composition. Serovars within a serogroup can also be found in different genomospecies 
(Greene et al., 2006). Despite this, various studies have tried to correlate serovars and 
serogroups with different clinical signs (Goldstein et al., 2006; Greenlee et al., 2004; Greenlee 
et al., 2005) and according to Greene et al. (2006) serovars icterohaemorrhagiae and pomona 
are believed to cause hepatic disease while canicola, bratislava and grippotyphosa cause renal 
or hepatic disease, although pomona has also been associated with renal disease.  
 
Hematology, blood chemistry and urinalysis  
The changes in hematology, blood chemistry and urine depend on the severity of the infection 
and the stage that the dog is in when the samples are taken. In studies about leptospirosis in 
dogs leucocytosis with a left-shifted neutrophilia and anemia was seen in more than 30% of 
the dogs (Birnbaum et al., 1998; Goldstein et al., 2006; Prescott et al., 2002). In those studies 
the number of dogs included varied between 31 and 54. In two of the mentioned studies more 
than 30% of the dogs had thrombocytopenia (Goldstein et al., 2006; Prescott et al., 2002), the 
corresponding number in the third study was 14% (Birnbaum et al., 1998). When evaluating 
the blood chemistry a very common finding is azotemia (elevated serum urea and creatinine). 
In three different studies more than 81% of the dogs had azotemia, in one study it was even 
found in more than 93% of the dogs. Other common changes in the blood chemistry in these 
studies were hyperphosphatemia (in >50%), increased alkaline phosphatase (ALKP) (in 
>50%) and increased alanine aminotransferase (ALT) (in approximately 30%) (Birnbaum et 
al., 1998; Goldstein et al., 2006; Prescott et al., 2002). Increased total bilirubin varied in the 
studies between 17% (Birnbaum et al., 1998) and 68% (Prescott et al., 2002). The bile acids 
can be increased in infected dogs (Greene et al., 2006). Goldstein et al. (2006) found that 31% 
of the dogs had hyperglobulinemia. According to Greene et al. (2006) hyperglobulinemia is 
probably due to a chronic stimulation arising from the leptospiral infection. It can also be due 
to dehydration, secondary to, for example, a renal failure. Dogs with leptospirosis can develop 
hypoalbuminemia and Goldstein et al. (2006) observed that in 35% of the dogs. Different 
 14 
 
electrolytic changes can be seen due to dysfunction in the kidneys and gastrointestinal organs. 
The most common electrolytic changes, apart from hyperphosphatemia, are hypo- or 
hyperkalemia, hyponatremia and hypochloremia (Goldstein et al., 2006; Prescott et al., 2002). 
Humans have additionally shown hypomagnesaemia apart from these findings, but this has 
not been observed in dogs. Calcium has a protein-bound fraction and because of the loss of 
albumin a mild hypocalcaemia can be seen in dogs with leptospirosis. If the dog suffers from 
a secondary pancreatitis the amylase, lipase and pancreatic lipase immunoreactivity (PLI) can 
be increased. Creatinine kinase (CK), C-reactive protein (CRP) and cardiac Troponin I can 
also be elevated in dogs with leptospirosis. The blood-pH can be lower than normal with a 
lower bicarbonate level (Greene et al., 2006).   
 
Common changes in the urine is a specific gravity below 1,029, tubular or glomerular 
proteinuria, increased protein/creatinine ratio, hematuria, pyuria and glucosuria (Birnbaum et 
al., 1998; Goldstein et al., 2006). Granular casts can also be seen (Greene et al., 2006). 
Proteinuria can be due to a renal loss of protein or inflammation in the urinary tract (Ettinger 
& Feldman, 2010). An elevated protein/creatinine ratio with a low-cellularity sediment 
indicates that the proteinuria is caused by decreased renal function (Greene et al., 2006).  
 
According to Greene et al. (2006) there is eventually a poorer prognosis for dogs with 
thrombocytopenia, hypoalbuminemia, increased cardiac Troponin I (which may indicate 
myocardial damage), increased C-reactive protein/haptoglobin ratio, increased urinary 
albumin or increased protein/creatinine ratio in urine.   
 
Diagnosis 
Direct analysis 
Cultivation 
Cultivation can be made from blood and urine and is a good way to know if the animal is 
actually infected with Leptospira. Unfortunately the cultivation can be time consuming, 
taking from a couple of days to four months, requiring weekly microscopic examination 
before it is possible to consider a sample as negative. This method is useful for epidemiologic 
studies as it gives the veterinarian a definitive diagnosis (Adler & Moctezuma, 2010). Blood 
can be used for cultivation up to ten days after infection. After that the concentration of 
leptospires is highest in the urine. Both blood and urine can be used if the time of infection is 
unknown (Sykes et al., 2011). The bacterium is secreted intermittently in the urine so repeated 
urine samples are recommended. Diuretics can be used prior to the urine collection to increase 
the shedding (Greene et al., 2006). If cultivation is chosen as a diagnostic method it is 
important to take the sample before treatment with antibiotics is initiated (Adler & 
Moctezuma, 2010).  
 
Microscopy 
Leptospires may be seen on microscopic evaluation of blood, urine, CSF and peritoneal or 
pleural exudate during the first 10 days of the infection (Faine et al., 1999; Levett, 2001). 
Dark field microscopy is required as the leptospires are very small (Picardeau, 2013; Zuerner, 
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Fig 2. Incubation of 
leptospires.  
 
Fig 3. Dark-field 
microscopy used at 
UNMSM.  
 
2010), however  more than 104 organism/ml are required to be able to see them. This method 
is insensitive and has a low specificity. When choosing a body fluid to analyze it is important 
to consider the pathogenesis and at what stage it is possible to detect the leptospires. For 
example, blood can only be used in the acute stage of the disease (Levett, 2001; Picardeau, 
2013). Dark field microscopy must be followed by serology or cultural diagnostic methods if 
it is desirable to specify the serovar. The leptospires can be seen with light microscopy if 
using either Giemsa stain or silver impregnation on air-dried smears (Greene et al., 2006). 
Immunoflourescence is also possible to use (Levett, 2001).  
 
Genetic detection 
Polymerase Chain Reaction (PCR) assays have been developed but are still not commonly 
used even though this method is reported to have a high sensitivity (Adler & Moctezuma, 
2010). Serum, urine, aqueous humor and tissues from autopsy have been used for PCR. 
Modern methods such as fragment length polymorphism (RFLP), pulse field gel 
electrophoresis (PFGE), 16S rRNA sequencing and other methods are currently being 
assessed (Adler & Moctezuma, 2010; Levett, 2001).  
 
Others 
There are other techniques available such as direct fluorescent antibody testing, agglutination-
adsorption techniques and radioimmunoassays but they are not widely used (Greene et al., 
2006; Levett, 2001).  
 
Indirect analysis 
The Microscopic Agglutination Test (MAT) 
MAT is considered the standard method for the serological diagnosis 
of leptospirosis (Levett, 2001). To execute MAT leptospires are 
grown in liquid media (Figure 2). Serum is mixed with the leptospires 
in order to test for agglutination. Agglutination indicates that the 
serum contains anti-Leptospira antibodies (Picardeau, 2013; Sykes et 
al., 2011). Antibodies are detectable from 5-7 days after infection 
(Levett, 2001). In a study by 
Limmathurotsaku et al. (2012) in humans, the 
sensitivity of MAT was found to be around 
50% and the specificity almost 100%. As the 
leptospires are thin and small, dark field 
microscopy is used to evaluate the agglutination (Figure 3). MAT is a 
serogroup specific diagnostic method and serovars are chosen as 
representatives for different serogroups (Miller et al., 2011; Picardeau, 
2013). The sera can cross-react between various serovars representing 
the serogroups, which makes it difficult to determine the infecting 
serovar, especially in the acute phase of infection (Levett, 2001; 
World Health Organization (WHO), 2003). The ability to predict the 
serogroup may be as low as 40% (Levett, 2001). In general, 
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Fig 4. Incubation of samples.  
 
laboratories analyze serovars that are present in their local area. Normally six to eight serovars 
are used compared to human laboratories where they often use about 20 serovars (Greene et 
al., 2006). 
 
Different dilutions are used to receive a titer. A positive sample is considered a sample with 
more than 50% agglutination. Analysis normally begins with the dilution 1/100 and a positive 
result in that dilution indicates a titer of 1/100 (Picardeau, 
2003; Sykes et al., 2011; WHO, 2003). At the Laboratory of 
Bacteriology at UNMSM the titers 1/100, 1/200, 1/400, 1/800 
and 1/1600 were used. The incubation protocol and incubation 
sheet used at UNMSM is shown in Figure 4. Sometimes the 
serum can react against many serogroups in the beginning of 
the infection but later shows the highest titer against the 
infecting strain (Levett, 2001). However this is currently 
debated (Sykes et al., 2011). According to Levett (2001) a 
four-fold increase in a paired sample or a single titer of more 
than 1/800 in an endemic area is required for the diagnosis of 
acute leptospirosis. In an area where cases of leptospirosis are 
rare, titers of >1/200 can be used as the cut-off point (Levett, 2001). According to Adler & 
Moctezuma (2010) a single titer of 1/400 or more is considered a positive sample. Levett 
(2001) suggests that if obvious symptoms of leptospirosis are present, 3-5 days between the 
samples is sufficient or 10-14 days if the patient is in the early stages of disease. Sometimes it 
takes longer for the antibodies to develop, up to 3-4 weeks or more (Faine et al., 1999).  
 
Agglutinating antibodies are most frequently IgM and IgG to a lesser extent. IgM 
concentrations fluctuate according to the presence of the organism (Greene et al., 2006, 
WHO, 2003). There are not many studies done to evaluate for how long the antibodies persist. 
Different studies have shown results between two and 20 years (Faine et al., 1999). If an 
animal is successfully treated with antibiotics the titer will decrease, however sometimes a 
titer of 1/200 as the most can be seen until 1-4 months after treatment (Greene et al., 2006).  
 
MAT has a high sensitivity and specificity but the difficulties are that live cultures of different 
serovars are necessary to carry out the method. It is also necessary that a trained person works 
with the samples and evaluates the results. MAT is not able to differentiate between 
antibodies from infection and from vaccination (Adler & Moctezuma, 2010, Picardeau, 2013).  
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
There are Enzyme-Linked Immunosorbent Assays (ELISA) that measure IgM and IgG 
against Leptospira. During early infection, IgM-detection with ELISA can be a more sensitive 
diagnostic method than MAT (Levett, 2001; WHO, 2003). If both IgG and IgM are measured, 
ELISA has been found to better distinguish between natural infection and vaccine-induced 
antibodies. However later in the infection the serovar specificity is lower than that of MAT. In 
general MAT is considered a method with greater sensitivity and specificity than ELISA and 
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therefore ELISA should not be used as a single diagnostic test (Adler & Moctezuma, 2010; 
Greene et al., 2006; WHO, 2003). 
 
Others 
There are other immunoassays such as a macroscopic slide agglutination test, latex-based 
agglutinations tests and commercial kits that measure IgG and IgM (Adler & Moctezuma, 
2010; Greene et al., 2006; Levett, 2001). When a sample is taken early in the course of 
disease, IgM detection is considered a more sensitive method than MAT (Levett, 2001).  
 
Treatment of leptospirosis in dogs 
The prognosis after treatment of leptospirosis can be good if the dog does not suffer from 
severe clinical signs and organ lesions. An early and aggressive treatment with antibiotics and 
fluids is required. A dog surviving a subacute infection may be considered healthy 2-3 weeks 
after infection. Urea and creatinine values are often normalized within 10-14 days but 
regeneration of kidney tissue can continue for a month (Sykes et al., 2011). The renal function 
can return after 2-3 weeks but if the function does not return there is a risk that the dog could 
have developed a chronic compensated polyuric renal failure (Greene et al., 2006). A dog that 
has suffered from thrombocytopenia and survives often shows an improved thrombocyte 
count within a week (Sykes et al., 2011).  
 
Antibiotic treatment 
According to Levett (2001) few well executed studies have been made about the treatment of 
leptospirosis with antibiotics. It is difficult to evaluate the results as many dogs come to the 
clinic in a late stage of the disease. By treating the dog with antibiotics the leptospiremia and 
fever can reduce. Multiplication of the leptospires with secondary pathologic changes in the 
kidney and liver are also avoided. The earlier in the course the antibiotics are given, the less is 
the risk of development of secondary chronic changes (Goldstein, 2010; Greene et al., 2006; 
Levett, 2001). Which antibiotic is best is actually not known. Penicillin works well against 
leptospiremia and is considered to diminish the renal and liver lesions caused by the infection, 
but it does not work well for elimination of the organism from the body (Adin & Cowgill, 
2000; Green et al., 2006; Sykes et al., 2011). Doxycycline has been found to eliminate 
leptospires from the body (Goldstein, 2010; Sykes et al., 2011). There are studies considering 
penicillin as the only treatment but many are afraid that chronic shedders develop if using 
only penicillin (Adin & Cowgill, 2000). There are also studies saying that penicillin is non-
effective (Levett, 2001). A dog that has a normal alimentation can start with oral treatment 
right away. To eliminate the bacteria as soon as possible doxycycline is the most common 
choice. In dogs that vomit, have uremia or are hepatically compromised, it is common to 
begin with parenteral penicillin or ampicillin and when the dog has regained a normal 
alimentation an oral treatment with amoxicillin or doxycycline is initiated (Goldstein, 2010). 
According to the Consensus Statements of the American College of Veterinary Internal 
Medicine (ACVIM), ampicillin should not be administered orally as it has a low absorption in 
the gastrointestinal tract (Sykes et al., 2011). Aminoglucosides are only used in dogs with 
normal renal function (indicated on a blood sample) as it is a nephrotoxic antibiotic. 
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Macrolides have been shown to be effective against leptospires but not as effective as 
penicillin and doxycycline. It has been suggested that macrolides can be used in clinically 
stable patients that are able to receive an oral treatment. Third-generation cephalosporins 
work well in cattle and humans but have not been widely used in dogs (Greene et al., 2006). 
Chloramphenicol and sulphonamides are ineffective whereas quinolones have an effect but 
are less effective than amoxicillin (Greene et al., 2006; Sykes et al., 2011). Neither are 
fluoroquinolones recommended as they contribute to the development of antimicrobial 
resistance in other bacteria (Sykes et al., 2011). If using tetracycline, high doses are necessary 
which may be nephrotoxic. Doxycycline is less nephrotoxic but can induce nausea and 
vomiting (Adin & Cowgill, 2000). Suggestions of doses for antimicrobial treatment of 
leptospirosis are found in Table 2. The given dose for doxycycline is also recommended by 
Goldstein (2010) and ACVIM, but ACVIM recommend a duration of two weeks or two 
weeks after the gastrointestinal signs are gone (Sykes et al., 2011). Doxycycline is mainly 
excreted in the feces so the dose does not have to be changed for dogs with renal failure 
(Greene et al., 2006). ACVIM recommends the same dose for penicillin G as Greene et al. 
(2006) or a dose of 20 mg/kg intravenously every six hours if using ampicillin (with dose 
reduction for azotemic dogs).  
 
Table 2. Antimicrobial treatment of leptospirosis (after Greene et al., 2006) 
DRUG Dose Administration Interval Duration (weeks) 
Penicillin G 25000-40000 IU/kg IM, SC, IV 12 hours 3 
Ampicillin 22 mg/kg SC, IV 6-8 hours 3 
 
20-40 mg/kg PO 8 hours 3 
Amoxicillin 10-20 mg/kg PO 8-12 hours 3 
Doxycycline 5 mg/kg PO, IV 12 hours 3 
Tetracycline 22 mg/kg PO 8 hours 3 
Azithromycin 20 mg/kg PO 24 hours 3 
IU = international units, IM = intramuscular, IV = intravenous, SC = subcutaneous, PO = per oral 
 
Supportive treatment 
The supportive treatment for leptospirosis depends on the dog and its needs. Patients with 
severe symptoms will need hospital care (Levett, 2001). If the dog is severely affected and in 
shock it will need fluid therapy. Fluid therapy is also necessary for dogs with fluid losses 
from diarrhea and vomiting. Fluids are chosen according to current electrolyte imbalances in 
the dog. If the dog is vomiting secondary to uremic gastritis gastric protectants such as H2-
receptor antagonists and proton-pump inhibitors can be used. It is important to consider 
parenteral treatment in vomiting dogs as oral treatment may be unhelpful. A dog with 
hemorrhages (petechial or ecchymotic) and thrombocytopenia may be in need of 
anticoagulation treatment. If the dog has hypoalbuminemia or if pancreatitis is suspected 
plasma or whole blood should be given (Birnbaum, 1998; Goldstein, 2010; Greene et al., 
2006).  
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A dog with oliguria (under 2 ml/kg/hour) should first be treated with fluids to become 
rehydrated. If the decrease in renal function persists, osmotic diuretics can be added (glucose 
10% or 20%, mannitol 20%) intravenously for 30-60 minutes. Dopamine or dopaminergic 
agents can be administered intravenously if osmotic diuretics do not work. Dopamine can be 
given together with furosemide to improve the effect. Peritoneal dialysis, hemodialysis or 
continuous renal replacement therapy can be used if oliguria cannot be treated with any of the 
mentioned drugs. Massive pulmonary hemorrhages are associated with high mortality in 
humans. To decrease the inflammation humans are treated with intravenous 
methylprednisolone, first with a shock-bolus dose for three days and then an anti-
inflammatory dose for seven days (Greene et al., 2006). ACVIM does not consider 
methylprednisolone helpful for massive pulmonary hemorrhages but suggests oxygen (Sykes 
et al., 2011). Humans are also treated with hemofiltration, plasma exchange therapy and 
cyclophosphamide but to know if these treatments are possible to use in dogs or not more 
studies are required (Greene et al., 2006).  
 
Prophylaxis 
Immunity and vaccination 
Immunity against Leptospira is mainly humoral although a cellular immunity may also be 
important. The antibodies that develop after an infection are directed against LPS in the outer 
membrane of the Leptospira. There are vaccines against leptospirosis and the ones in current 
use are inactivated (Faine et al., 1999; Greene et al., 2006). During clinical trials vaccines on 
the market have prevented disease and to a great extent shedding of leptospires in the urine 
(Sykes et al., 2011). Hartman et al. (1984) found that IgM-antibodies reached a maximum 
concentration one week after a vaccination (serovar canicola and icterohaemorrhagiae) and 
could be measured until seven weeks after. With a booster vaccination after 3-4 weeks IgG-
titers could be measured at a maximum after one week but after six months the titers were 
low. After the revaccination after six months the IgG-titers were high for approximately one 
year.  
 
ACVIM recommends a revaccination annually. A dog that has recovered from leptospirosis 
should also be vaccinated as the persistence of the antibodies is uncertain (Sykes et al., 2011). 
As the disease is considered rare in Sweden the recommendation for vaccination is only 
focused on dogs that will visit another country in Europe and spend time close to water, in 
woodlands, in places with many dogs or at a farm. Vaccination is not considered necessary 
when travelling to one of the other Nordic countries. In Sweden it is most common to use a 
vaccine containing the serovars icterohaemorrhagiae and canicola (The National Veterinary 
Institute (SVA), 2011). Vaccines that, aside from serovar canicola and icterohaemorrhagiae, 
also include serovar grippotyphosa and pomona are available in North America (Sykes et al., 
2011) and also in Peru. The recommendation for vaccination in Sweden is two vaccinations 
with a 3-4 weeks interval. The second injection is done 1-3 month before travelling. The dog 
is then revaccinated after 6 months, thereafter annually (SVA, 2011).  
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Cleaning of an infected environment 
When cleaning environments with suspected contamination it is important to not only use 
water as the leptospires can survive for a long time in infected urine diluted with water 
(Babudieri, 1958; Greene et al., 2006). 10% bleach solution, iodine-based disinfectants, 
accelerated hydrogen peroxide and quaternary ammonium solution can be used as 
disinfectants (Greene et al., 2006: Sykes et al., 2011). It is important to use gloves and wash 
hands whilst working with infected dogs and infected urine.  
 
PART 2, FIELD STUDY 
Aims 
The aims of this study were as follows: 
 
• To describe the changes in hematology, blood chemistry and urinalysis that 
Leptospira can cause in dogs before and after treatment by analyzing blood and 
urine samples from dogs diagnosed with leptospirosis at UNMSM   
• To describe the levels of serum antibodies acting against Leptospira before and 
after treatment in dogs diagnosed with leptospirosis at UNMSM 
• To describe the effect of treatment in dogs diagnosed with leptospirosis at the 
aforementioned clinic 
 
Material and methods 
Study population and study design 
The field study was carried out at UNMSM during the period 10th of September – 2nd of 
November 2012 (8 weeks). The study was made as a Minor Field Study funded by SIDA 
(Swedish International Development Cooperation Agency) in Sweden.  
 
Dogs that fulfilled the following criteria were included:   
 
• Examined and treated at the Small Animal Clinic, UNMSM or the private owned 
clinic GuauGuau Wasi in Lima 
• Received a positive serologic result (all titers) for Leptospira by MAT (serovars 
australis, bratislava, canicola, georgia, grippotyphosa, icterohaemorrhagiae, 
pomona) at the Laboratory of Bacteriology, UNMSM during the period 10th of 
August – 2nd of November (one month before the beginning of the field period 
till the end of the field study period, explanation below) 
• Owners agreed to participate in the study 
 
Dogs of all ages, breeds and sexes were included in the study.  
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Blood and urine samples 
Blood and urine samples were taken when the dog came to clinic for a first consultation and 
again after one month of treatment. The blood samples included in the study are summarized 
in Table 3 with the urinalysis in Table 4.  
 
Table 3. Blood samples included in the study 
SAMPLE Test Instrument Laboratory 
edTA 
Hematology 
Abacus 5, junior vet Microscopy 
Laboratory of 
Clinical 
Pathology, 
UNMSM 
Thrombocyte count 
Serum 
Creatinine 
Wiener laboratory test 
Urea 
Total protein 
Albumin 
ALT (alanine aminotransferase) 
ALKP (alkaline phosphatase) 
Phosphate 
Microscopic Agglutination test (MAT) According to 
“Instrucciones de la técnica de MAT 
del Instituto Nacional de Salud” (Oficina  
General de Epidemiología,  
Instituto Nacional de Salud, 2000) 
Laboratory of 
Bacteriology, 
UNMSM 
Serovars: australis, bratislava, canicola, 
georgia, grippotyphosa, 
icterohaemorrhagiae, pomona 
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Table 4. Urine samples included in the study 
SAMPLE Test Instrument Laboratory 
Urine 
pH 
Urine sticks 
Laboratory of Clinical Pathology 
Glucose 
Bilirubin 
Urobilinogen 
Ketones 
Hemoglobin 
Blood 
Nitrite 
Protein 
Sulfocalicylic acid test (SAA) 
Nitric Acid Test 
Leucocytes 
Microscopy  
(Congo Red included) 
Erythrocytes 
Bacteria 
Cylinders 
Crystals 
Cells 
Specific gravity Refractometer 
Color 
Manually 
Aspect 
Protein/creatinine ratio EMT-168 VetDiagnóstics 
 
Statistical analyses 
Values for hematology (basophiles, eosinophiles, erythrocytes, hemoglobin, hematocrite, 
leucocytes, lymphocytes, monocytes, neutrophiles, thrombocytes), blood chemistry (albumin, 
ALKP, ALT, creatinine, phosphate, total protein, urea) and selected urinalyses (specific 
gravity, protein and protein/creatinine ratio) were evaluated statistically. The Shapiro Wilk 
Normality Test was first used to investigate if the variables were normally distributed or not 
(Z>0,05 = normally distributed) (Petrie & Watson, 2001). A paired T-test was used to 
compare analytic results before and after treatment for normally distributed, numeric 
variables. For the variables with Z<0,05 (not normally distributed) a histogram was made to 
investigate if the variables had a left- or right-tailed distribution. For data sets with a right-
tailed distribution the data was normalized by taking the base 10 logarithm of each 
observation. The distribution of logarithmically transformed data will often be approximately 
normal for right-tailed variables (Petrie & Watson, 2001). The logarithmic values received 
were used for the paired T-test. For data sets with a left-tailed distribution (only 
thrombocytes) the Wilcoxon Signed-Rank Test was used. The variable proteinuria was 
measured qualitatively and therefore the Sign Test was used to compare the medians of the 
variable before and after one month of treatment. A p-value of <0,05 was considered 
statistically significant in all statistical analyses (Petrie & Watson, 2001). All statistical 
analyses were conducted using the software STATA 11.  
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Collection of epidemiological data 
Information about the history, anamnesis, clinical signs and treatment of the dogs was 
collected from the paper records kept at UNMSM. To gather more information about the dogs 
included in the study a questionnaire was filled out by the owner (appendix 1). The 
questionnaire contained questions about the dog, the owner, clinical signs seen in the dogs 
and the owner’s knowledge about leptospirosis. There is always a risk for recall bias if the 
owners do not remember the correct answers or avoid answering truthfully, however a 
questionnaire with the same questions for all the owners makes it possible to summarize their 
answers.  
 
Results 
Description of included dogs 
All dogs that received a positive result on MAT were included, irrespective of their titer. 
During the field study period ten dogs received a positive result. Two owners of dogs with 
positive results declined to participate and two owners agreed to participate but did not come 
for their follow-up analyses, which resulted in six dogs participating. To include more dogs in 
the study, all owners of dogs that received a positive result on MAT within one month before 
the field study period and that fulfilled the inclusion criteria were asked to participate in the 
study. Four dogs entered the study this way, one owner declined. This resulted in a total 
sample population of ten dogs. The dogs diagnosed with leptospirosis before the field study 
period did not have all the necessary analyses for the project. This was considered when 
evaluating the results.  
 
All the owners (n=10) with dogs included in the study filled out a questionnaire (appendix 1). 
Results showed that out of the ten included dogs, six were mixed breed, four were pure breed 
and six were male. The age varied from 7 months to 12 years, five were between 7 months 
and 4 years, two between 5 and 8 years and three between 8 and 12 years. Three came for 
their first consultation in August, four in September and three in October. The dogs included 
in the study are summarized in Table 5. 
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Table 5. Information about the included dogs 
DOG Dates for consultation
1 Breed Age Sex 
   
Years f/m 
  B A 
   
1 7-12/9 12/10 Mixed 12 M 
2 10/8 19/9 Yorkshire 1 M 
3 15-17/8 19/9 Schnauzer 8,5 M 
4 18-21/9 20/10 Mixed 4 F2 
5 18-21/9 20/10 Weimaraner 1 F 
6 4/9 4/10 Mixed 0,6 F 
7 15-20/8 25/9 Scottish terrier 6 M 
8 26/9-5/10 31/10 Pekingese 7 F2 
9 1-5/10 24/10 Mixed 1 M 
10 3-5/10 30-31/10 Poodle 12 M 
. = parameter not included in the history, 1 = Samples collected during that period, 2 = castrated, A = 
after treatment, B = before treatment, , F = female, M = male 
 
Out of the ten dogs studied seven had received a vaccination against Leptospira, three had 
not. Of the vaccinated dogs five received their vaccination in 2011 and two received one in 
2012. Five were vaccinated with Pfizer Vanguard 5L4, a vaccine currently used at UNMSM. 
This vaccine contains the serovars canicola, grippotyphosa, icterohaemorrhagiae and pomona. 
The remaining two were vaccinated with a vaccine containing the serovars canicola and 
icterohaemorrhagiae.  
 
The most common clinical signs reported in the ten questionnaires were depression (n=6), 
vomiting (n=5), diarrhea (n=4) and polydipsia (n=4). Other less common clinical signs were, 
in decreasing order, darker urine than before (n=3), fever (n=3), polyuria (n=2) and 
hemorrhages (n=2). When asked, two of the owners thought their dog moved less than 
normal. No dog suffered from pain according to their owners.  
 
Three of the dogs had received a positive titer against Toxoplasma gondii during the field 
study period or within one month before (No. 1, 3 & 6). 10% (1/10) suffered from 
myxomatous mitral valve disease (No. 10).  
 
Blood analyses 
Hematology 
None of the dogs had anemia (erythrocytes<5, hemoglobin (Hb)<12, hematocrite (HCT)<37) 
at their first consultation nor at their follow-up after one month of treatment. Leucocytosis 
was found in seven and neutrophilia (segmented neutrophils) in nine of the dogs before 
treatment. The leucocyte count decreased in all the dogs after treatment except for one which 
was within normal ranges both before and after treatment but three dogs that had leucocytosis 
initially still had values above normal range for leucocytes. The neutrophilia decreased in six 
of the dogs but nine still had values above normal range for segmented neutrophils after 
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treatment. Both the decrease in leucocytes and neutrophiles was found to be statistically 
robust at the p=0,05 level. The dogs included in the study had a value of zero on basophiles, 
monocytes and neutrophiles (myelocytes, metamyelocytes and banded), therefore these values 
could not be analyzed statistically. The results from hematology including the statistical 
analyses are found in Table 6, 7 and 8.  
 
Table 6. Results Hematology, part 1/2, values outside the normal reference range indicated with a 
bold and underlined style 
DOG 
Erya 
 
Hba 
 
HCTa 
 
Leucb 
 
Troa 
 
Eosa 
 
Basod 
x106/ul 
 
g/dl 
 
% 
 
x103/ul 
 
x103/ul 
 
1-5% 
 
0-0,5% 
5-7 
 
12-18 
 
37-55 
 
8-13 
 
200-400 
 
80-650/ul 
 
0-65/ul 
  B A 
 
B A 
 
B A 
 
B A 
 
B A 
 
B A 
 
B A 
1 7 7 
 
15,3 16 
 
48 49 
 
6,8 13,86 
 
400 
 
416 0 0 
 
0 0 
2 7 6,79 
 
16 14,4 
 
46 41 
 
10,95 10,29 
 
394 292 
 
2 2 
 
0 0 
3 5,1 7,52 
 
14,9 13,5 
 
49 
 
35 12,45 15,41 
 
397 
 
196 3 3 
 
0 0 
4 6,9 
 
7,8 16,4 
 
19 48 
 
55 11,46 10,9 
 
289 337 
 
2 1 
 
0 0 
5 7,5 
 
8,3 17,7 16,8 
 
50 54 
 
16,25 
 
13,5 300 285 
 
2 0 
 
0 0 
6 6,8 
 
7,3 14,9 16 
 
43 48 
 
9,77 14,37 
 
199 
 
173 1 2 
 
0 0 
7 8,5 
 
7,8 18 17,2 
 
53 50 
 
20,37 
 
18,4 397 420 
 
1 0 
 
0 0 
8 6,9 7,2 
 
15 16 
 
38 48 
 
8,3 20 
 
428 
 
479 0 2 
 
0 0 
9 6,8 
 
8,4 15,4 17 
 
44 51 
 
8,34 9,8 
 
282 196 
 
2 0 
 
0 0 
10 6,7 7,27 
 
16,8 16 
 
49 50 
 
26,42 
 
13,76 350 430 
 
0 4 
 
0 0 
a = non-significant at p = 0,05, b = significant at p = 0,05, d = not possible to receive a result, A = after 
treatment, B = before treatment, Baso = basophiles, Eos = eosinophiles, Ery = erythrocytes, Hb = 
hemoglobin, HCT = hematocrite, Leuc = leucocytes, Tro = thrombocytes 
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Table 7. Results Hematology, part 2/2, values outside the normal reference range indicated with a 
bold and underlined style 
DOG 
Neutb 
 
Lyma 
 
Monod 
Myel 
 
Met 
 
Band 
 
Segm 
      
0% 
 
0% 
 
0-3% 
 
65-75% 
 
15-30% 
 
1-4% 
0/ul 
 
0/ul 
 
0-390/ul 
 
5200-9750/ul 
 
1200-3900/ul 
 
80-520/ul 
  B A 
 
B A 
 
B A 
 
B A 
 
B A 
 
B A 
1 0 0 
 
0 0 
 
0 0 
 
81 
 
84 19 16 
 
0 0 
2 0 0 
 
0 0 
 
0 0 
 
88 
 
80 18 10 
 
0 0 
3 0 0 
 
0 0 
 
0 0 
 
81 
 
77 16 20 
 
0 0 
4 0 0 
 
0 0 
 
0 0 
 
75 89 
 
9 24 
 
0 0 
5 0 0 
 
0 0 
 
0 0 
 
80 
 
80 18 20 
 
0 0 
6 0 0 
 
0 0 
 
0 0 
 
89 
 
63 10 
 
35 0 0 
7 0 0 
 
0 0 
 
0 0 
 
91 
 
90 6 
 
10 2 0 
8 0 0 
 
0 0 
 
0 0 
 
93 
 
86 7 12 
 
0 0 
9 0 0 
 
0 0 
 
0 0 
 
74 
 
80 24 20 
 
0 0 
10 0 0 
 
0 0 
 
0 0 
 
90 
 
82 8 
 
14 2 0 
a = non-significant at p = 0,05, b = significant at p = 0,05, d = not possible to receive a result, A = after 
treatment, B = before treatment, Band = banded, Lym = lymphocytes, Met = metamyelocytes, Mono = 
monocytes, Myel = myelocytes, Neut = neutrophiles, Segm = segmented 
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Table 8. Statistical analyses of hematology variables, software STATA11 
VARIABLE 
Shapiro-Wilk 
 
Distribution 
 
Wilcoxon 
 
Paired T-test 
Z > 0,05 = normal value 
 
R = right-tailed 
 
p > 0,05 = non-significant 
 
p > 0,05 = non-significant 
Z < 0,05 = not normal value 
 
L = left-tailed 
 
p < 0,05 = significant 
 
p < 0,05 = significant 
   
logarithm (base 10) 
        
   analyzed if not 
normal value 
 analyzed if not 
normal value 
 analyzed if not normal value, left-tailed 
distribution 
 analyzed if normal value + not normal value, 
right-tailed distribution      
      
  B A 
 
B A 
         
Ery 0,02 0,33 
 
0,04 0,11 
 
R . 
 
. . 
 
0,41 NS 
Hb 0,13 0,94 
 
. . 
 
. . 
 
. . 
 
0,63 NS 
HCT 0,68 0,11 
 
. . 
 
. . 
 
. . 
 
0,71 NS 
Leuc 0,75 0,61 
 
. . 
 
. . 
 
. . 
 
0,01 S 
Thro 0,02 0,91 
 
0,01 0,61 
 
L . 
 
0,51 NS 
 
. . 
Eos 0,14 0,71 
 
. . 
 
. . 
 
. . 
 
0,57 NS 
Baso - - 
 
. . 
 
. . 
 
. . 
 
. . 
Neut (myel) - - 
 
. . 
 
. . 
 
. . 
 
. . 
Neut (met) - - 
 
. . 
 
. . 
 
. . 
 
. . 
Neut (band) - - 
 
. . 
 
. . 
 
. . 
 
. . 
Neut (segm) 0,23 0,38 
 
. . 
 
. . 
 
. . 
 
0,04 S 
Lym 0,20 0,36 
 
. . 
 
. . 
 
. . 
 
0,98 NS 
Mono 0,01 - 
 
. . 
 
. . 
 
. . 
 
. . 
. = parameter not analyzed, - = value 0, not possible to receive a result, A = after treatment, B = before 
treatment, Band = banded, Baso = basophiles, Eos = eosinophiles, Ery = erythrocytes, Hb = 
hemoglobin, HCT = hematocrite, Leuc = leucocytes, Lym = lymphocytes, Met = metamyelocytes, 
Mono = monocytes, Myel = myelocytes, Neut = neutrophiles, NS = non-significant at p=0,05, S = 
significant at p=0,05, Segm = segmented, Thro = thrombocytes 
 
Blood Chemistry 
Dogs with higher creatinine (n=2), urea (n=8), ALT (n=3) or ALKP (n=4) than normal before 
treatment were found. The values decreased in many of the dogs but were still above normal 
range in one out of two dogs (creatinine), six out of eight (urea), one out of three (ALT) and 
three out of four (ALKP). In three out of eight dogs with an increased urea level before 
treatment, the urea increased despite the treatment. None of the dogs had hypoalbuminemia 
before nor after treatment. None of the dogs had hyperphosphatemia before treatment but it 
was found in three after treatment. None of the changes in blood chemistry were statistically 
robust at the p=0,05 level. The results from blood chemistry, including the statistical analyses, 
are found in Table 9 and 10.     
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Table 9. Results Blood Chemistry, values outside the normal reference range indicated with a bold 
and underlined style 
DOG 
Creaa 
 
Ureaa 
 
TPa 
 
Alba 
 
ALTa 
 
ALKPa 
 
Phosa 
mg/dl 
 
mg/dl 
 
g/dl 
 
g/dl 
 
UI/L 
 
UI/L 
 
mg/dl 
< 1,6 
 
10—30 
 
5,5-7,5 
 
2,3-3,2 
 
< 50 
 
< 190 
 
2,4-5 
  B A 
 
B A 
 
B A 
 
B A 
 
B A 
 
B A 
 
B A 
1 1,5 
 
2,4 40 
 
61 5,4 
 
5,4 2,7 2,5 
 
91 
 
82 1283 
 
790 4,8 3,9 
2 1,5 1,6 
 
39 
 
55 5 6,3 
 
2,9 2,8 
 
. 
 
136 . 189 
 
. 4,9 
3 2,1 
 
1,9 62 
 
58 . 5,8 
 
. 2,7 
 
40 48 
 
. 136 
 
. 4 
4 1,4 1,9 
 
28 16 
 
6,9 6,1 
 
4 3,9 
 
39 32 
 
827 
 
404 3,3 6 
5 1,6 1,5 
 
25 32 
 
6 
 
7,9 3,9 
 
4,2 36 32 
 
143 160 
 
3,9 7 
6 1,2 1,6 
 
33 
 
32 8,2 
 
5,1 3,9 
 
3,3 40 69 
 
391 
 
298 . 
7 
1,5 
1,5 1,5 
 
27 21 
 
. 6,8 
 
. 
 
3,9 . 
 
140 . 
 
196 . 3,8 
8 2 1,5 
 
20 54 
 
5,9 
 
5,3 2,6 2,8 
 
36 61 
 
113 159 
 
3,1 2,7 
9 1,4 1,6 
 
39 
 
34 5 5,6 
 
2,8 3,6 
 
25 35 
 
111 120 
 
2,1 
10 
5,3 
1,6 
 
2,8 54 
 
61 6,2 6,1 
 
2,7 3,7 
 
49 
 
53 180 402 
 
3,6 3,6 
. = parameter not analyzed, a = non-significant at p = 0,05, A = after treatment, B = before treatment, 
Alb = albumin, ALKP = alkaline phosphatase, ALT = alanine aminotransferase, Crea = creatinine, 
Phos = phosphate, TP = total protein 
 
Table 10. Statistical analyses of biochemistry variables, software STATA11 
VARIABLE 
Shapiro-Wilk 
 
Distribution 
 
Paired T-test 
Z > 0,05 = normal value 
 
R = right-tailed 
 
p > 0,05 = non-significant 
Z < 0,05 = not normal value 
 
L = left-tailed 
 
p < 0,05 = significant 
   
logarithm (base 10) 
      
   analyzed if not normal 
value 
 analyzed if not 
normal value 
 analyzed if normal value + not normal value, right-tailed 
distribution      
    
  B A 
 
B A 
 
B A 
   
Crea 0,55 0,01 
 
0,73 0,02 
 
. R 
 
0,78 NS 
Urea 0,22 0,25 
 
. . 
 
. . 
 
0,31 NS 
TP 0,28 0,25 
 
. . 
 
. . 
 
0,43 NS 
Alb 0,28 0,04 
 
0,20 0,06 
 
. R 
 
0,08 NS 
ALT 0,59 0,00 
 
0,97 0,03 
 
. R 
 
0,17 NS 
ALKP 0,08 0,00 
 
0,31 0,08 
 
. R 
 
0,09 NS 
Phos 0,97 0,98 
 
. . 
 
. . 
 
0,92 NS 
. = parameter not analyzed, A = after treatment, B = before treatment, Alb = albumin, ALKP = 
alkaline phosphatase, ALT = alanine aminotransferase, Crea = creatinine, NS = non-significant at 
p=0,05, Phos = phosphate, TP = total protein 
 
Microscopic Agglutination Test (MAT) 
All dogs included in the study had at least a titer of 1/100 against one of the serovars. A titer 
of 1/400 or more was observed in two dogs, the remaining dogs had a lower titer. Three dogs 
had a titer against more than one serovar at the first consultation and six had a negative result 
on MAT at their follow up. The rest of the dogs received a positive titer against the same 
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serovar as before the treatment and eventually against other serovars too. Six dogs received a 
positive titer against a serovar included in the vaccine they got in 2011 or 2012. The results 
from MAT and information about vaccination included, are found in Table 11.  
 
Table 11. Results on MAT 
DOG 
Serovar 
Aus  Bra  Can  Geo  Gri  Ict  Pom 
neg  Neg  neg  neg  neg  neg  neg 
B A   B A   B A   B A   B A   B A   B A 
1 . . 
 
. . 
 
1/200 . 
 
. . 
 
. . 
 
. . 
 
. . 
2 . . 
 
--- . 
 
. . 
 
. . 
 
1/1001 . 
 
. . 
 
. . 
3 . . 
 
. . 
 
. 1/2001 
 
. . 
 
1/1001 1/1001 
 
. . 
 
. 1/4001 
4 1/100 . 
 
. . 
 
. . 
 
. . 
 
. . 
 
. . 
 
. . 
5 . . 
 
. . 
 
1/1001 . 
 
. . 
 
1/1001 . 
 
. . 
 
1/2001 1/2001 
6 . . 
 
1/200 . 
 
. . 
 
. . 
 
. . 
 
. . 
 
. . 
7 . . 
 
. . 
 
. . 
 
. . 
 
1/200 . 
 
. . 
 
. . 
8 . . 
 
1/100 1/100  1/800
1 . 
 
. . 
 
1/100 1/200 
 
. . 
 
1/200 . 
9 . . 
 
. . 
 
. . 
 
. . 
 
. . 
 
. . 
 
1/1002 1/4002 
10 . .   . .   1/2002 .   . .   . .   . .   1/400 . 
Total 1 0   2 1   4 1   0 0   5 2   0 0   4 3 
Total 
vaccinated 
- -  - -  2 (2011) 1 (2011)  - -  3 (2011) 1 (2011)  0 0  1 (2011) 2 (2011) 
            1 (2012)                       1 (2012) 1 (2012) 
. = negative, --- = serovar not analyzed, - = no vaccine containing serovar available, 1 = vaccinated 
with vaccine including that serovar 2011, 2 = vaccinated with vaccine including that serovar 2012, Aus 
= Australis, Bra = Bratislava, Can = Canicola, Geo = Georgia, Gri = Grippotyphosa, Ict = 
Icterohaemorrhagiae, Pom = Pomona 
 
Urinalysis 
More than 50% of the dogs had a lower or higher specific gravity than normal before and 
after treatment. One dog had a higher specific gravity than normal both before and after 
treatment, however the other dogs did not have alternations in specific gravity that endured 
after treatment. In seven out of nine studied dogs proteinuria with >3+ on the sulphosalicylic 
test (SAA) and/or the nitric acid test (NAT) before treatment was found. According to urine 
stick tests four of these dogs also had hematuria (according to analysis of the urine sediment 
two additional dogs had few erythrocytes in their urine, bringing the total number of dogs 
with hematuria according to the urine sediment to six). Four of the dogs with proteinuria 
(n=7) before treatment still had a value above normal range after treatment. None of these 
dogs had hematuria at the follow-up according to urine stick tests (three dogs had few 
erythrocytes in the urine according to the sediment). The decrease in proteinuria after 
treatment was significant at the p=0,05 level. A regular amount of leucocytes in the urine 
before treatment was observed in four out of nine dogs. One of these four dogs had several 
leucocytes in the urine after treatment, the others were negative. Another dog that had few 
leucocytes in the urine before treatment had a regular amount after treatment. Five out of nine 
dogs had granular cylinders in their urine before treatment. After treatment these dogs no 
longer had granular cylinders in their urine, however two dogs, one that was negative for 
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cylinders before treatment (No. 2) and one without a urine sample before treatment (No. 3), 
had granular cylinders in their urine after treatment. The results of specific gravity, 
protein/creatinine ratio and proteins, including the statistical analyses, are found in Table 12 
and 13.  
 
Table 12. Results of specific gravity, protein/creatinine ratio and protein, values outside the normal 
reference range indicated with a bold and underlined style 
DOG 
Refractometer 
 
EMT-168 
 
SAA/NAT 
Spec grava 
 
P/C ratioa 
 
Prob 
1,025-1,035 
 
< 1 
 
neg/tr (0/1) 
  B A 
 
B A 
 
B B (nr) A A (nr) 
1 1,035 1,035 
 
0,51 2,26 
 
4 +++ 3 ++ 
2 1,055 
 
1,055 . 0,78 
 
3 ++ 3 ++ 
3 . 1,032 
 
. 0,84 
 
. . 3 ++ 
4 1,037 
 
1,014 0,41 0,36 
 
4 +++ neg 0 
5 1,028 1,018 
 
0,92 0,13 
 
Tr 1 neg 0 
6 1,03 1,026 
 
. 0,59 
 
Tr 1 tr 1 
7 1,025 
 
1,015 . 
 
1,07 4 +++ 3 ++ 
8 1,035 
 
1,018 0,75 0,83 
 
4 +++ neg 0 
9 1,01 
 
1,042 0,8 
 
1,86 4 +++ 3 ++ 
10 1,049 
 
1,019 0,57 1,6 
 
3 ++ tr 1 
. = parameter not analyzed, a = non-significant at p = 0,05, b = significant at p = 0,05, A = after 
treatment, B = before treatment, NAT = nitric acid test, Neg = negative, Nr = number, Pro = protein, 
P/C ratio = protein/creatinine ratio, SAA = sulphosalicylic acid test, Spec grav = specific gravity, Tr = 
trace  
 
Table 13. Statistical analyses of urine variables, software STATA11 
VARIABLE 
Shapiro-Wilk 
 
Paired T-test 
 
Sign Test 
Z > 0,05 = normal value 
 
p > 0,05 = non-significant 
 
p > 0,05 = non-significant 
Z < 0,05 = not normal value 
 
p < 0,05 = significant 
 
p < 0,05 = significant 
   
logarithm (base 10) 
      
   analyzed if not 
normal value 
 analyzed if normal value + not normal value, right-
tailed distribution 
 analyzed is qualitative 
variable      
    
  B A 
 
B A 
      
Spec grav 0,97 0,40 
 
. . 
 
0,24 NS 
 
. . 
P/C ratio 0,34 0,18 
 
. . 
 
0,18 NS 
 
. . 
Pro . . 
 
. . 
 
. . 
 
0,02 S 
. = parameter not analyzed, A = after treatment, B = before treatment, NS = non-significant at p=0,05, 
Pro = protein, P/C ratio = protein/creatinine ratio, S = significant at p=0,05, Spec grav = specific 
gravity  
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Treatment 
Antibiotics 
All of the dogs (n=10) received some kind of antimicrobial treatment and nine received 
doxycycline. Four out of nine received the dose recommended by ACVIM, Goldstein (2010) 
and Greene et al. (2006) (5 mg/kg every 12 hours). Of the dogs that received doxycycline five 
had previously received treatment with benzylpenicillin, ampicillin or amoxicillin at the clinic 
prior to the oral treatment with doxycycline at home. A compilation of the antimicrobial 
treatment received by the dogs is found in Table 14.    
 
Table 14. Compilation of the antimicrobial treatment received by the dogs studied 
DOG 
BP Amp Amo Dox Trim/sulpha Other 
Dose Dur 
Adm 
Dose Dur 
Adm 
Dose Dur 
Adm 
Dose Dur 
Adm 
Dose Dur 
Adm  
IU/kg days mg/kg days mg/kg days mg/kg days mg/kg days 
 
1 . . . 22/12h 4 IV . . . 5/12h 20+141 PO . . . Cli3 
2 . . . . . . . . . 10/12h 28 PO . . . . 
3 
. . . . . . 15/24h 5 IM 5/24h 15 PO . . . Cli3 
. . . . . . . . . 15/24h 20 PO . . . . 
4 . . . . . . . . . 5/12h 28 PO . . . . 
5 
. . . . . . . . . 5/12h 28 PO . . . . 
30000 6 IM . . . . . . 5/12h 7+7+72 PO . . . . 
6 . . . . . . . . . 10/12h 30 PO . . . Cli, oxy 
7 . . . . . . . . . . . . 24/12h 7 - . 
8 20000 4 - . . . . . . 4/12h 14 PO . . . Cep 
9 . . . . . . 18/- 2 IM 5/12h 14 PO . . . . 
10 . . . . . . . . . 8/12h 15+51 PO . . . . 
. = not given, - = not mentioned, 1 = The treatment was prolonged, 2 = 7 days treatment, 7 days rest x 
3, 3 = against toxoplasmosis, Adm = method of administration, Amp = ampicillin, Amo = amoxicillin, 
BP = benzylpenicillin, Cep = cephalotin/cephalexin, Cli = clindamycin, Dox = doxycycline, Dur = 
duration, IU = international units, IV = intravenously, IM = intramuscular, Oxy = oxytetracycline, PO 
= per oral, Trim/sulpha = trimethoprim/sulphonamide 
 
Supportive treatment 
Almost all the dogs (n=9) received some kind of supportive treatment (fluid therapy, antacida, 
antiemeticum, vitamins, silymarin or others). A compilation of the supportive treatment the 
dogs received is found in Table 15.    
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Table 15. Compilation of the supportive treatment received by the dogs studied 
DOG Fluids Antacida Antiemeticum Vitamins Silymarin Other 
SP RL NaCl Ran Ome Sucr Meto Amino Gli Hep 
  
1 + + + + + . + + . + . Dex, LM, Sedo, Tram, Diet 
2 . . + + . . + . . . . Diet k/d 
3 + +1 . . . . + . . + . . 
4 . . . + . . . . . . + Diet 
5 . . . + + + + . . . + 
 
6 + . + + + . + + . + . Meta, Dex, Pred, NSAID2 
7 . . . . . . . . . . . . 
8 + + . + . . + . + + + Diet 
9 . . + + . . . . . . . Tram, Dron, skin gel 
10 . . + . . . . . . . + Fur, Dig, Enal, Spi, Theo 
1 = dextrose added, 2 = local treatment in eyes, Amino = aminoplex, Dex = dexamethasone, Dig = 
digoxine, Dron = droncit, Enal = enalaprile, Fur = furosemide, Gli = glicopan, Hep = hepatina or 
hepabionta, LM = leche de magnesia (laxative), Meta = metamizole, Meto = metoclopramide, Ome = 
omeprazole, Pred = prednisolone, Ran = Ranitidine, RL = Ringer Lactate, Sed = sedotropine (anti-
bloating), SP = suera polielectrolítica, Spi = spironolactone, Sucr = sucralphate Theo = theophylline, 
Tram = tramadol 
 
Discussion 
Included dogs 
During the field study period at UNMSM ten dogs participated in the study. This was a small 
group of dogs which makes it difficult to draw firm conclusions about leptospirosis in dogs in 
general based on the result in the studied dogs. All dogs did not have all the analyses included 
in the study which made the study sample even smaller for some of the variables. A control 
group with healthy dogs was not included in this study. With a control group a comparison of 
changes in blood and urine samples could have been made between healthy and ill animals. It 
would also have been possible to compare serological results in clinically healthy dogs and 
dogs with clinical signs. All the dogs that fulfilled the inclusion criteria and received a 
positive titer on MAT entered the study but the dogs that received a negative result on their 
first consultation were not included. It is possible that some of the dogs were in an acute stage 
of the disease and had not yet seroconverted. A new MAT after approximately two weeks 
would have been appropriate in the seronegative dogs, but in general this would not have been 
economically possible for the study nor for the owners. In order to include as many dogs as 
possible no discrimination on basis of breed, age or sex was made. To investigate the 
prevalence and lesions in different categories of dogs, a bigger group and a longer field study 
period would be required.   
 
Clinical findings 
Clinical signs 
Depression, vomiting, diarrhea and polydipsia were the most common clinical signs in this 
study. Anorexia has been found in 67-75% of dogs in other studies (Birnbaum et al., 1998, 
 33 
 
Prescott et al., 2002; Goldstein et al., 2006). Anorexia was not included as a question in the 
questionnaire for the owners and only one owner wrote it in the “Other” column. This could 
be the reason why anorexia was not a common clinical sign in this study.  
 
Blood analyses  
In a study done by Goldstein et al. (2006) 53% (29/54) of the dogs had anemia. Anemia can 
be due to acute renal failure with over hydration, chronic renal failure with decreased 
production of erythropoietin, chronic inflammatory disease or acute blood loss due to tissue 
thrombosis and/or acute hemorrhaging in the gastrointestinal tract or the respiratory organs 
(Greene et al., 2006). In this study none of the dogs had low hematocrite either before or after 
treatment. This could be a true finding or could be due to a false-normal hematocrite if the 
dogs suffered from both anemia and dehydration (Ettinger & Feldman, 2010). In this study, 
the decrease in leucocytosis and neutrophilia was found to be statistically robust (p=0,05). 
This could be due to a decreased inflammatory response attributed to the treatment (Ettinger 
& Feldman, 2010). However, even if a significantly robust decrease was seen, many of the 
dogs still had values above normal range after treatment, especially the dogs with 
neutrophilia, indicating that the inflammation was still ongoing.  
 
When describing blood chemistry changes in dogs with leptospirosis, azotemia (increased 
urea and creatinine) is almost always seen as a primary finding. Some of the dogs that came to 
the clinic before the field study, and were included later, did not have comprehensive blood 
chemistry results available, however all of them had at least urea and creatinine measured 
previously. Goldstein et al. (2006)’s finding of 93% azotemic dogs in a group with 
leptospirosis emphases the need to evaluate levels of urea and creatinine in dogs with this 
disease. The renal and liver enzymes were higher than normal in many of the dogs in the 
study. They decreased in some dogs after treatment, however they were still observed to be 
above normal range in several dogs. The urea value even increased in some dogs despite 
treatment. None of the changes in blood chemistry were statistically robust (p=0,05). It is 
therefore not possible to draw conclusions about any improvement in blood chemistry due to 
the treatment. In the dogs with higher values than normal after treatment, chronic lesions in 
the kidneys and/or liver could have been developed. Studies have shown that if urea and 
creatinine are increased, a minimum of 75% of the nephrons must have lost their function 
(Ettinger & Feldman, 2010; Greene et al., 2006). To better investigate the liver function bile 
acids can be evaluated (Ettinger & Feldman, 2010) but this analysis in not currently used at 
the Laboratory of Clinical Pathology, UNMSM. In a study by Goldstein et al. (2006) 78% of 
the dogs had developed hyperphosphatemia. Birnbaum et al. (1998) found hyperphosphatemia 
in 50% of the dogs. With those high numbers it is suggested to take a phosphate sample in 
dogs suspected or diagnosed with leptospirosis. The development of hyperphosphatemia 
could be due to development of a renal failure, but it can also be due to delayed serum 
separation, dietary excess, hemolysis or another cause (Ettinger & Feldman, 2010). Goldstein 
et al. (2006) and Prescott et al. (2002) found different electrolytic changes in dogs with 
leptospirosis such as hyponatremia, hypo- or hyperkalemia and hypochloremia. An evaluation 
of electrolytes was not included in the study as the consultation with blood and urine samples 
could not be too expensive for the owners participating in the study.  
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Four of the dogs had been diagnosed with other diseases as well, three with toxoplasmosis 
and one with myxomatous mitral valve disease. These diseases could have contributed to the 
changes in hematology, blood chemistry and urinalysis that were found in the studied dogs 
and the titers against Leptospira could have been an incidental finding. Other diseases that the 
dogs were not tested for could also have contributed to the changes.  
 
Urinalysis 
The specific gravity of urine is a complex parameter as the results depend on the water intake 
and the current status of the animals. A dog can have a changed specific gravity in one urine 
sample and a normal value in another. To investigate if the dog has a decreased possibility to 
concentrate its urine, two urine samples from different occasions should be analyzed. If the 
dog has decreased specific gravity in both of them a concentration disability could be 
suspected (Ettinger & Feldman, 2010). The urine specific gravity in the dogs in the study 
deviated both above and below normal values but none of them had a lower specific gravity 
both before and after treatment. However 40% (4/10) of the dogs had a lower specific gravity 
than normal after treatment and it is recommended that these dogs are reexamined in the 
future, in order to see if they still have a low specific gravity, a finding that could indicate a 
decreased renal or hepatic function.  
 
According to the sulphosalicylic acid test (SAA) and the nitric acid test half of the included 
dogs had proteinuria after treatment. Only two of these dogs had an increased 
protein/creatinine ratio. In a study by Lyon et al. (2010) the protein/creatinine was found to be 
a very specific method so the ability to correctly identify negative samples was good 
(specificity of 99,7% in dogs) but it had low sensitivity (28,7%). The SAA had moderate 
specificity and a poor positive predictive value (Lyon et al., 2010). The decrease in 
proteinuria after treatment was found to be statistically robust (p=0,05). It is important to 
consider that although there was a significant decrease in proteinuria several dogs still had 
values above the normal range. Proteinuria can be due to a renal loss of protein or 
inflammation in the urinary tract (Ettinger & Feldman, 2010). Proteinuria with a low 
cellularity-sediment is something that can indicate that proteins are being lost through the 
kidneys. Therefore, before taking renal disease into consideration, it is important to examine 
the urine sediment and see if there are many cells there (Greene et al., 2006). It is also 
important to compare these results with other parameters, such as urine specific gravity, 
presence of granular casts in urine, albumin, creatinine and urea values in blood etc.   
 
Diagnosis with MAT 
A problem with MAT is that it cannot differentiate between antibodies due to vaccination and 
those from infection (Adler & Moctezuma, 2010). Many of the dogs were vaccinated during 
2011 or 2012 and the majority of them received low MAT-titers. According to 
recommendations for vaccination the dogs should be vaccinated annually to maintain the 
protection (Sykes et al., 2011). However in studies involving humans, detectable antibodies 
have been found after up to 20 years (Faine et al., 1999) so it could be possible that the dogs 
still have antibodies circulating in their blood. Therefore it is very important to consider 
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whether the dog has received a vaccination against Leptospira when evaluating the MAT 
results and compare the results with other findings and clinical signs. This is also why a 
paired test with at least a four-fold increase or a titer of at least 1/400 (Adler & Moctezuma, 
2001) or 1/800 (Levett, 2001) is recommended.  
 
Only two dogs received a titer above 1/400 in this study. As mentioned above, antibodies 
have shown to persist for a long time and a seropositive test, above all low titers, do not equal 
an acute infection. However all the studied dogs received antimicrobial treatment. It is 
important to have in mind that the veterinarians who treat these dogs are dealing with a 
zoonotic disease and that the dogs are often in a very bad shape due to one or many diseases. 
Therefore, if the dog is ill, has clinical signs and clinical findings in accordance with 
leptospirosis and also has a positive result on MAT, even though it is a low titer, a treatment 
is often initiated.  
 
If the dog is successfully treated with antibiotics the titer will decrease. Agglutinating 
antibodies that react in MAT are mainly IgM and IgG to a lesser extent. IgM increases and 
decreases according to the presence of the organism (Greene et al., 2006; WHO, 2003). This 
could probably explain why the titers on MAT would be decreased after a successful 
treatment. Sometimes a titer of 1/200 at the most can be seen during 1-4 months after 
treatment and this can be due to a long-term persistence or replication of the bacteria (Greene 
et al., 2006). This could have been the case in the dogs with titers against one or many 
serovars after treatment. The initial titer and the change in titer do not seem to correlate with 
the severity of the disease (Greene et al., 2006).  
 
An important consideration with MAT is that cultivation and survival of the leptospires are 
important to be able to execute the test. The results are evaluated manually and are therefore 
subjective. A dog can also suffer from a serovar that is not included in MAT at that laboratory 
or there could be a weak reaction against the serovar chosen as representative for the 
serogroup (Greene et al., 2006).  
 
Treatment 
The most common choice of antibiotic treatment in this study and earlier studies was 
doxycycline, probably because the veterinarians want to use antibiotics that can eliminate the 
bacterium from the body. Doxycycline is also mainly excreted in the feces so the dose does 
not have to be changed for dogs with renal failure (Greene et al., 2006). However 
development of antimicrobial resistance also has to be considered before starting the 
treatment. According to the guidelines for the clinical use of antibiotics in the treatment of 
dogs and cats, formed by the Swedish Veterinary Association (SVS) (original 2002, revised 
2009) there has to be evidence of infection before starting a treatment with antibiotics. More 
studies with clearly defined groups are needed to evaluate the best choice of antibiotics. The 
most common choice at UNMSM is doxycycline at a dose of 5 mg/kg/12 hours, a dose 
recommended by trustworthy sources (Goldstein, 2010; Greene et al., 2006; Sykes et al., 
2011). However Goldstein (2010) and Greene et al. (2006) consider three weeks an 
appropriate duration while ACVIM recommend two weeks. The duration of the treatment in 
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the studied dogs varied between 14 and 28 days. The duration of treatment probably has to be 
corrected for the individual patient. Some may need a longer treatment and others shorter, but 
a minimum of two weeks seems to be appropriate. 
 
Conclusions  
For dogs with leptospirosis according to this study: 
 
• The most common changes in hematology were leucocytosis and neutrophilia 
(anemia and thrombocytopenia were not found in this study but are important 
findings in other studies) 
• The most common changes in blood chemistry were increased urea and 
creatinine, increased ALT, increased ALKP and hyperphosphatemia 
(hypoalbuminemia was not found in this study but is an important finding in 
other studies) 
• The most common changes in urinalysis were proteinuria, pyuria, hematuria and 
presence of granular casts (persistent low specific gravity was not found in this 
study but is an important finding in other studies) 
• The treatment significantly decreased the leucocytosis, neutrophilia and 
proteinuria (p=0,05) but not always to a level within the normal range  
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APPENDIX 
1. Questionnaire for owners (originally in Spanish) 
Project about leptospirosis in dog in Lima, Peru  
You have received a questionnaire with questions about You and Your dog. The questionnaire 
form part of a thesis about leptospirosis in dogs in Lima, Peru, that Sophie Hedberg, 
veterinary student, 6th year, Sweden, is currently working with.   
   Leptospirosis is a bacterial disease that can affect different animals, for example dogs and 
also humans. The bacterium enters the body via the skin or mucous membranes. Leptospira is 
transmitted to dogs and humans via, for example, urine from infected animals. Humans can 
also be infected when drinking contaminated water. The clinical manifestation of the disease 
is fever, signs of renal and hepatic disease (vomits, diarrhea etc) and mucous membrane 
bleeding.  
   Your dog has symptoms that could be caused by an infection with Leptospira. The 
diagnosis is not yet confirmed. If your dog is diagnosed with Leptospira (analyses in blood 
and urine) You can participate in the project.  
 
The aims of the project: 
• Analyze the presence of Leptospira in urine in dogs 
• Analyze the antibody level against Leptospira in blood in dogs 
• Evaluate the renal and hepatic lesions that Leptospira can cause 
(hematology, blood chemistry, urine) 
• Analyze samples of blood and urine after one month of treatment to be 
able to compare the renal and hepatic lesions and the level of antibodies in 
blood before and after one month of treatment 
 
Advantages for You if Your dog participates in the project:  
• One analysis gratuitous at the first consultation 
• Follow-up consultation with the veterinarian after one month of treatment 
free of charge, in addition to all the analyses gratuitous 
 
The first consultation is paid by You as the owner/responsible of the dog and the project pays 
for one additional analysis. The follow-up consultation after one month is very important for 
us to be able to make a comparison of the renal and hepatic lesions before and after the 
treatment. Besides, we’ll establish if Your dog needs a special diet and/or continue its 
treatment. If You’d like to participate in the project it’s very important that You and the dog 
come for a follow-up consultation after one month.  
   If You’d like to participate in the project, You’ll receive information about the recovery of 
Your dog and that way understand the effect of the treatment. At the same time You 
contribute to the investigation about the bacterium Leptospira in dogs in Lima, Peru. All the 
final information about the dogs and owners is confidential.  
Yes, I’d like to participate in the project about leptospirosis in dogs in Lima, Peru 
Yes O No O Date:  
  Key:  
Owner/responsible   
Signature  First and last name 
   
  
 DNI:  
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Questions for You Key:  
 
1. The owner 
a. Residence in Lima, Peru  
 i. Name of district   
 ii. Name of urbanization  
 iii. Name of neighborhood  
b. Type of living  
 i. House (one family) O  
 ii. House (more than one 
family)  O  
 iii. Apartment O  
 iv. Other O 1. What? 
c. More dogs at home?   
 i. Yes O 1. Number:  2. Age/ages: 
 ii. No O      
d. Other types of animals at home?   
 i. Yes O 1. What kind of animal?  
 ii. No O (production animals, domestic animals as cats etc)  
  
2. The dog 
a. Breed  
 i. Pure breed O 1. What breed?  
 ii. Mixed O 1. What breeds (if You know?) 
b. Age  
c. In what space does the dog spend most of its time?   
 i. Inside O 1. Flat roof O 
   2. Garden O 
   3. Rooms/Other O 
 ii. Outside (street) O  
 iii. Other O 1. Where? 
d. Who takes care of the dog at home?  
 i. The man O (possibility to choose more than one alternative)  
 ii. The woman O   
 iii. The kids O   
 iv. Other person O 1. Who? 
e. To whom did it occur having a dog?    
 i. The man O (possibility to choose more than one alternative) 
 ii. The woman O   
 iii. The kids O   
 iv. Other person O 1. Who? 
f. From where did You acquire 
the dog?   
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g. When did You acquire the 
dog?   
 i. <6 month O  
 ii. >6 month O   
h. What diet does the dog get?   
 i. Balanced O  
 ii. Homemade O   
 iii. Mixed (bal/ho) O   
 iv. Other O 1. What? 
  
3. More questions  
a. Why did You come to 
the clinic with your dog 
today?  
 
 
b. Which symptoms has 
Your dog shown?  
   a. Times/day? 
b.  
Since when?  
i. Vomiting 
1. 
Yes O    2. 
No O 
ii. Diarrhea 
1. 
Yes O    2. 
No O 
iii. Urinates more 
frequently 
1. 
Yes O    2. 
No O 
iv. Urine darker 
than before  
1. 
Yes O  ----  2. 
No O 
v. Drinks more 
water than before  
1. 
Yes O  ----  2. 
No O 
 
vi. Hemorrhages 
1. 
Yes O  ----  2. 
No O 
i. Where did you 
notice them?      
1. Mouth O  4. Urine O    
2. Skin O  5. Other  
3. Feces O   
vii. Other 1. Pain O ---  
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2. Depressed O ---  
3. Moves little O ---  
4. Fever O ---  
i. How much?   
5. 
Other    
     
c. Do You know home 
many times a day Your 
dog urinates when it’s 
healthy?  
a) < 2 times/day 
b) 3-4 times/day 
c) > 5 times/day 
 
d. Have You contacted 
another veterinarian 
concerning this disease 
(leptospirosis) the last 5 
days? If the answer is 
“Yes”, what treatment did 
the veterinarian prescript 
for the dog? 
i. Yes O ii. No O i. Times/day? 
ii. Since 
when? 
1. Antibiotics 
a. 
Yes O    
b. 
No O    
2. Fluids 
a. 
Yes O    
b. 
No O    
3. Other 
     
   
e. Did You know anything 
about Leptospirosis before 
You came to the clinic 
today? If the answer is 
“Yes”, what did You 
know about the disease?  
 
 
 
f. Has the dog been ill 
owing to this disease 
before? If the answer is 
“Yes”, when?  
 
 
 
g. Do You know if there 
are other dogs in the 
neighborhood that have 
fallen in owing to 
Leptospirosis?  
 
 
 
h. Is the dog vaccinated 
against Leptospira? If the  
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answer is “Yes”, when did 
it get the last vaccination? 
Please, show us the 
vaccination certificate.  
i. Do You know if Your 
dog suffers from other 
illnesses? If the answer is 
“Yes”, which? And what 
treatment does it get for 
this?  
i. Yes O ii. No O   
 
a. 
¿Which
? 
b. Medicine c. Times/day? 
d. Since 
when? 
1. Ill 1     
2. Ill 2     
3. Ill 3     
4. Ill 4     
j. Has the dog had other 
illnesses such as 
Distemper or Parvovirus 
previously? Confirmed or 
suspected? 
 
 
 
k. Does the dog use to 
bring dead animals at 
home such as for example 
rodents, birds etc? If the 
answer is “Yes”, what 
kind of animals?  
 
 
 
Thank you very much for participating in the project and for 
filling out the questionnaire!  
 
 
Sophie Hedberg 
Veterinary student, 6th year, Uppsala, Sweden    
 
